Journal:

Article Title: Immune-Directed Gene Therapeutic Development for Alzheimer's, Prion, and Parkinson's Diseases

doi: 10.1007/s11481-008-9133-3

Figure Lengend Snippet: Immunotherapy for neurodegenerative diseases. AD, TSE, and PD share a common hallmark pathobiologic feature of misfolded toxic proteins. In this review, we discuss the use of both active and passive vaccination approaches to decrease the amount of the toxic moieties. a Active vaccination utilizing HSV amplicon delivery of Aβ and IL-4 shaped the immune response toward TH2 in a mouse model of AD decreasing the Aβ plaque levels (Frazer et al. 2008). b Passive vaccination of scrapie-challenged mice with rAAVscFvPrPC decreased the PrPSc burden and improved clinical and behavioral outcome measurements (Wuertzer et al. 2008). c Anti-SYN scFv have been identified with preferential binding to monomeric and/or protofibrillar SYN conformers (Emadi et al. 2004, 2007; Zhou et al. 2004; Maguire-Zeiss et al. 2006; Lynch et al. 2008). Subsets of these scFv have demonstrable efficacy in preventing SYN aggregation (Emadi et al. 2004; Zhou et al. 2004; Emadi et al. 2007; Lynch et al. 2008). In this schematic, we also consider scFv that may accelerate the formation of toxic oligomers to larger nontoxic aggregates

Article Snippet: Using monomeric, aggregated, and dopamine-modified SYN, we interrogated a human scFv phage display library for sequence and conformation-specific anti-SYN binders ( Maguire-Zeiss et al. 2006 ).

Techniques: Amplification, Binding Assay